Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joan Torras

Showing results (91-100 of 107) with videos related to

Pageof 11
Sort By:
Plos One|March 20, 2012
Delayed mTOR inhibition with low dose of everolimus reduces TGFβ expression, attenuates proteinuria and renal damage in the renal mass reduction modelMelania Kurdián, Inmaculada Herrero-Fresneda, Nuria Lloberas, et al.
Kidney International|June 21, 2013
Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantationOriol Bestard, Josep M Cruzado, Marc Lucia, et al.
Kidney International|June 30, 2023
A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian PredictionNuria Lloberas, Josep M Grinyó, Helena Colom, et al.
Atencion Primaria|July 3, 2026
Trough-to-peak ratios and elimination half-lives of antihypertensive drugs: implications for 24-hour blood pressure control in primary careMar Serrat-Costa, Gabriel Coll de Tuero, Ernest Vinyoles Bargalló, et al.
Pharmaceutics|May 27, 2023
The Effect of Intracellular Tacrolimus Exposure on Calcineurin Inhibition in Immediate- and Extended-Release Tacrolimus FormulationsPere Fontova, Lisanne N van Merendonk, Anna Vidal-Alabró, et al.
Clinical Pharmacology and Therapeutics|February 24, 2021
Sustained Inhibition of Calcineurin Activity With a Melt-Dose Once-daily Tacrolimus Formulation in Renal Transplant RecipientsPere Fontova, Helena Colom, Raül Rigo-Bonnin, et al.
Therapeutic Drug Monitoring|December 8, 2025
Tacrolimus Conversion in CYP3A5*1 Expressers: From Immediate-Release to LCP FormulationAnna Vidal-Alabró, Pere Fontova, Zeyar Mohammed Ali, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 21, 2020
Cellular Immunity to Predict the Risk of Cytomegalovirus Infection in Kidney Transplantation: A Prospective, Interventional, Multicenter Clinical TrialMarta Jarque, Elena Crespo, Edoardo Melilli, et al.
Kidney International Reports|October 26, 2020
A Comprehensive Phenotypic and Functional Immune Analysis Unravels Circulating Anti-Phospholipase A2 Receptor Antibody Secreting Cells in Membranous Nephropathy PatientsChiara Cantarelli, Marta Jarque, Andrea Angeletti, et al.
Kidney & Blood Pressure Research|March 21, 2018
Fabry Nephropathy: An Evidence-Based Narrative ReviewMaría Del Pino, Amado Andrés, Ana Ávila Bernabéu, et al.
Pageof 11

Showing results (91-100 of 107) with videos related to

Sort By:
Pageof 11
Plos One|March 20, 2012
Delayed mTOR inhibition with low dose of everolimus reduces TGFβ expression, attenuates proteinuria and renal damage in the renal mass reduction modelMelania Kurdián, Inmaculada Herrero-Fresneda, Nuria Lloberas, et al.
Kidney International|June 21, 2013
Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantationOriol Bestard, Josep M Cruzado, Marc Lucia, et al.
Kidney International|June 30, 2023
A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian PredictionNuria Lloberas, Josep M Grinyó, Helena Colom, et al.
Atencion Primaria|July 3, 2026
Trough-to-peak ratios and elimination half-lives of antihypertensive drugs: implications for 24-hour blood pressure control in primary careMar Serrat-Costa, Gabriel Coll de Tuero, Ernest Vinyoles Bargalló, et al.
Pharmaceutics|May 27, 2023
The Effect of Intracellular Tacrolimus Exposure on Calcineurin Inhibition in Immediate- and Extended-Release Tacrolimus FormulationsPere Fontova, Lisanne N van Merendonk, Anna Vidal-Alabró, et al.
Clinical Pharmacology and Therapeutics|February 24, 2021
Sustained Inhibition of Calcineurin Activity With a Melt-Dose Once-daily Tacrolimus Formulation in Renal Transplant RecipientsPere Fontova, Helena Colom, Raül Rigo-Bonnin, et al.
Therapeutic Drug Monitoring|December 8, 2025
Tacrolimus Conversion in CYP3A5*1 Expressers: From Immediate-Release to LCP FormulationAnna Vidal-Alabró, Pere Fontova, Zeyar Mohammed Ali, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 21, 2020
Cellular Immunity to Predict the Risk of Cytomegalovirus Infection in Kidney Transplantation: A Prospective, Interventional, Multicenter Clinical TrialMarta Jarque, Elena Crespo, Edoardo Melilli, et al.
Kidney International Reports|October 26, 2020
A Comprehensive Phenotypic and Functional Immune Analysis Unravels Circulating Anti-Phospholipase A2 Receptor Antibody Secreting Cells in Membranous Nephropathy PatientsChiara Cantarelli, Marta Jarque, Andrea Angeletti, et al.
Kidney & Blood Pressure Research|March 21, 2018
Fabry Nephropathy: An Evidence-Based Narrative ReviewMaría Del Pino, Amado Andrés, Ana Ávila Bernabéu, et al.
Pageof 11